Wassil Jim sold $1.6M of PCVX
Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 18,000 shares of Vaxcyte, Inc. (PCVX) at $86.74 ($1.56M total) on 2026-10-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership, which can be interpreted as a bearish sign, but the pre‑arranged 10b5‑1 plan may mitigate negative sentiment.
Market read
The filing introduces new insider‑sell data that could influence short‑term price action for PCVX.
What to watch
Potential upcoming clinical milestones that could offset the sell pressure.
Background
Form 4 filings provide the first public record of insider transactions, which traders monitor for clues about management's view of the company.
Ticker impact
EVP Wassil Jim sold 18,000 shares of Vaxcyte for $1.56M via a 10b5‑1 plan, reducing his stake to 145,435 shares.
potential downward pressure as the market prices the insider sell.
The sale is sizable for a mid‑cap biotech and was disclosed via a Form 4, making it a primary source of new information.
Market effects
May prompt scrutiny of Vaxcyte's pipeline and upcoming data releases.
Limited to U.S. biotech investors.
Low; impact confined to the company's shareholders.
Counterpoint
The sale could be a routine liquidity move, not a negative signal.
Key entities
- CompanyVaxcyte, Inc.
Biotech firm developing mRNA‑based therapeutics.
- IndividualWassil Jim
Executive Vice President, Chief Scientific Officer and COO of Vaxcyte.
